Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Merck Seeking Vorapaxar, Tredaptive Approval

By Drug Discovery Trends Editor | August 27, 2012

WHITEHOUSE STATION, N.J. (AP) — Merck & Co. said it will file for U.S. and European marketing approval of its experimental blood thinner vorapaxar and cholesterol drug Tredaptive in 2013.

Merck said it will complete a late-stage clinical trial of Tredaptive later in 2012 and will file for approval in 2013.

The company said it will ask regulators to approve vorapaxar for the prevention of cardiovascular events like heart attacks in patients with a history of heart attack and no history of transient ischemic attacks or strokes. The company originally hoped to get a broader approval of vorapaxar, but studies showed that while it lowered the risk of cardiovascular events it also raised the risk of major bleeding, including dangerous bleeding in the head.

BMO Capital Markets analyst Dave Shove said he has serious concerns about the demand for both drugs. He said Tredaptive may meet its goals in clinical testing, but if approved, the drug would face tough competition from generic versions of Abbott Laboratories Inc.’s Niaspan, and predicted sales will reach about $420 million in 2015.

He said vorapaxar’s side effects are a major concern. “We have low expectations based on modest reductions in cardiovascular events and significantly higher risk of serious bleeding,” he said.

The company also said it expects to complete a study of a third drug, anacetrapib, in 2017. Shove said anacetrapib is Merck’s most promising cardiovascular drug, although he had expected the company to complete its current study a year earlier, in 2016.

Date: August 27, 2012
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE